NDASUBCUTANEOUSSOLUTION
Approved
Jul 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
LYMPHAZURIN (isosulfan blue) by Medtronic is 12. Approved for breast cancer. First approved in 1981.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LYMPHAZURIN (isosulfan blue) is a vital dye administered subcutaneously that binds to serum proteins and is selectively taken up by lymphatic vessels, enabling visualization during lymph node mapping procedures in breast cancer surgery. The drug delineates lymphatic anatomy intraoperatively, facilitating sentinel lymph node biopsy and staging. Up to 10% of the dose is excreted unchanged in urine within 24 hours.
LOE Approaching
As a mature, non-innovative adjunct product approaching loss of exclusivity with minimal linked job postings, this product likely operates as a stable cash generator with minimal commercial expansion investment.
Mechanism of Action
12.2 Pharmacodynamics Following subcutaneous administration, isosulfan blue injection 1% binds to serum proteins and is picked up by the lymphatic vessels. Thus, the lymphatic vessels are delineated by the blue dye. 12.3 Pharmacokinetics Up to 10% of the subcutaneously administered dose of…
Indications (1)
Career Relevance
LYMPHAZURIN offers limited career growth opportunity due to zero linked job postings, approaching LOE status, and minimal commercial investment. Roles on this product tend toward operational management and relationship-focused selling rather than strategic launches or innovation-driven development.
Worked on LYMPHAZURIN at Medtronic? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.